A Quality-Adjusted Life-Year Measure for Multiple Sclerosis: Developing a Patient-Reported Health State Classification System for a Multiple Sclerosis-Specific Preference-Based Measure  by Goodwin, Elizabeth & Green, Colin
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 1 6 – 1 0 2 41098-3015$36.00 – s
Outcomes Research
http://dx.doi.org/10
E-mail: e.goodwi
* Address corresp
Campus, Exeter EX1journal homepage: www.elsevier .com/ locate / jva lPreference-Based AssessmentsA Quality-Adjusted Life-Year Measure for Multiple Sclerosis:
Developing a Patient-Reported Health State Classiﬁcation
System for a Multiple Sclerosis-Speciﬁc
Preference-Based Measure
Elizabeth Goodwin, PhD1,*, Colin Green, PhD1,2
1Health Economics Group, University of Exeter Medical School, University of Exeter, Exeter, UK; 2Collaboration for Leadership in
Applied Health Research and Care South West Peninsula, University of Exeter Medical School, University of Exeter, Exeter, UKA B S T R A C TBackground: Increasingly, generic preference-based measures of
health-related quality of life (HRQOL) are used to estimate quality-
adjusted life-years to inform resource allocation decisions. Evidence
suggests that generic measures may not be appropriate for multiple
sclerosis (MS). Objectives: To report the ﬁrst stage in the development
of an MS-speciﬁc preference-based measure to quantify the impact of
MS and its treatment: deriving a health state classiﬁcation system,
which is amenable to valuation, from the 29-item Multiple Sclerosis
Impact Scale (MSIS-29), a widely used patient-reported outcome
measure in MS. Methods: The dimensional structure of the MSIS-29
was determined using factor analysis and a conceptual framework of
HRQOL in MS. Item performance was assessed, using Rasch analysis
and psychometric criteria, to enable the selection of one item to
represent each dimension of HRQOL covered by the MSIS-29. Analysis
was undertaken using a sample (N ¼ 529) from a longitudinal study of
people with MS. Results were validated by repeating the analysis with
a second sample (N ¼ 528). Results: Factor analysis conﬁrmed theee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.07.002
n@exeter.ac.uk.
ondence to: Elizabeth Goodwin, Health Economics
2LU, UK.two-subscale structure of the MSIS-29. Both subscales covered
several conceptually independent dimensions of HRQOL. Follow-
ing Rasch and psychometric analysis, an eight-dimensional
classiﬁcation system named the MSIS-8D was developed. Each
dimension was represented by one item with four response
levels. Conclusions: Combining factor analysis with conceptual
mapping, and Rasch analysis with psychometric criteria, provides a
valid method of constructing a classiﬁcation system for an MS-
speciﬁc preference-based measure. The next stage is to obtain
preference weights so that the measure can be used in studies
investigating MS.
Keywords: health-related quality of life, health states, multiple
sclerosis, preference-based measures of health, quality-adjusted life-
years, Rasch analysis.
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Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Cost-utility analysis is a frequently used technique for evaluating
the cost-effectiveness of health care interventions, in which
quality-adjusted life-years (QALYs) are used to compare the rela-
tive merits of treatment options in terms of their impact on both
length and quality of life. QALYs are calculated by weighting each
year of life according to its quality on a scale ranging from 1
(equivalent to full health) to 0 (equivalent to being dead). Increas-
ingly, preference-based measures (PBMs) of health-related quality
of life (HRQOL) are used to provide these quality weights. PBMs use
a standardized classiﬁcation system to describe a ﬁnite number of
possible health states. Each unique health state is assigned a
numerical quality weight, typically estimated by eliciting prefer-
ences between different health states from a sample of the generalpopulation [1]. Cost-utility analyses commonly use generic PBMs,
such as the EuroQol ﬁve-dimensional questionnaire [2], Short-Form
6D [3], or Health Utilities Index [4], which are considered applicable
for all health conditions. The broad focus of these generic meas-
ures has given rise to debate around the extent to which they
capture aspects of HRQOL of particular relevance to speciﬁc health
conditions [5]. The assessment of QALYs in MS is one such case.
Multiple sclerosis (MS) is a neurological condition that affects
the central nervous system. It is a complex and progressive
condition causing a wide range of symptoms including spasticity,
loss of mobility, fatigue, ataxia, and loss of vision. The incidence
and severity of symptoms differ considerably between individu-
als and levels of disability increase as the disease progresses [6].
There is empirical evidence to suggest that generic measures
may lack the relevance and sensitivity required to capture theon behalf of International Society for Pharmacoeconomics and
Group, Institute of Health Research, South Cloisters, St Luke’s
Table 1 – Criteria for selection of an HRQOL
instrument.
Acceptability Single instrument, rather than
battery of measures*
Proportion of questionnaires
completed
Item missing data o10%
High percentage of computable scale
scores
Floor and ceiling effects o20% per
subscale
Does the range of scores span the
full-scale range?
Mean score near scale midpoint
Reliability Internal consistency (Cronbach α 4
0.80)
Test-retest reliability (r Z 0.50)
Construct validity Convergent validity (correlation r 4
0.70)
Discriminant validity (correlation r
4 0.30)
Group differences validity (P o 0.05)
Internal validity Moderate correlations between
subscales (0.30 o r o 0.70)
Responsiveness Effect size: large (40.80) or moderate
(40.50)
Scale development and
scaling assumptions
Recognized scale development
techniques used to devise the
instrument*
Similar mean scores and variances
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 1 6 – 1 0 2 4 1017many and varied effects of MS on people’s HRQOL [7–9] and that
they have limited ability to capture changes in HRQOL across the
full range of condition severity [7,10–13]. A recent systematic
review [14] reports an assessment of the psychometric properties
of several generic PBMs when applied to MS, ﬁnding that each
has its own limitations. The review concludes that the develop-
ment of an MS-speciﬁc PBM is a possible area for future research.
Condition-speciﬁc PBMs (CSPBMs) focus on those aspects of
health that are most relevant to the condition of interest,
potentially providing greater sensitivity to differences and
changes in HRQOL [1]. One approach is to develop a PBM from
an existing condition-speciﬁc measure. This process has been
reported for a range of conditions, including dementia [15],
mental health problems [16], asthma [17], ﬂushing [18], and
overactive bladder [19]. Here, we describe the ﬁrst stage in the
development of a CSPBM for MS: deriving a health state classi-
ﬁcation system from the 29-item Multiple Sclerosis Impact Scale
(MSIS-29).
The MSIS-29 is a widely used measure of HRQOL in MS with
strong psychometric properties. It consists of a physical sub-
scale of 20 items and a psychological subscale of 9 items.
Respondents are requested to report the impact of MS on their
day-to-day lives over the preceding 2 weeks. The amended
version, MSIS-29-v2, was used for this study; this has four
response levels per item: “not at all,” “a little,” “moderately,”
and “extremely.” The content of the instrument was based on
qualitative work with people with MS and is designed to be
suitable for all types of MS [20].
We begin by summarizing the basis on which we selected the
MSIS-29, followed by methods used for the development of the
classiﬁcation system and results.Similar response option frequency
distributions
Similar and substantial item–total
correlations (r 4 0.30)
Item–total exceed item–other
correlations by Z2 standard errors
Skewness (–1 to þ1)
Content/face validity The underlying concept captured by
the instrument is HRQOL*
Instrument was constructed on the
basis of qualitative work with
patients*
Extent to which instrument covers
domains important for HRQOL in
MS*
Practical considerations Acceptability to clinicians/
researchers; use in clinical trials
Access to a data set that includes the
measure
HRQOL, health-related quality of life; MS, multiple sclerosis.
* Indicates that this was used as a screening criterion (stage one).Measures of HRQOL for MS
Taking as a starting point that only patient-reported measures of
HRQOL provide a suitable basis for the development of a classi-
ﬁcation system for a CSPBM [21], a systematic search of the
literature was undertaken to identify existing MS-speciﬁc,
patient-reported HRQOL instruments. The search identiﬁed 13
published reviews of HRQOL measures in MS, from which 17
individual measures were extracted. The existing literature [22–
27] was used to develop criteria for assessing the quality of these
17 instruments. These criteria (Table 1) deﬁned our prerequisites
for any potential candidate measure for the CSPBM. A two-stage
approach was used, ﬁrst applying ﬁve initial criteria to narrow
down the selection without need for detailed comparison of
measures. Second, the remaining measures were compared
against the remaining selection criteria.
At stage one, 14 measures were excluded [12,28–38]. Exclu-
sions were primarily due to the development methodology not
incorporating qualitative research with patients (NeuroQoL Qual-
ity of Life in Neurological Conditions Measure, MS Quality of Life
Inventory, RAYS Quality of Life Scale for MS, Disability and
Impact Proﬁle, Health-Related Quality Of Life questionnaire for
MS, MS Activities of Daily Living Scales, MS Quality of Life-54,
Hamburg Quality of Life Questionnaire in MS, Functional Index
for Living with MS, and Quality of life Index MS version) and/or
recognized scale development techniques (MS Quality of Life
Inventory, Quality of Life Questionnaire for MS, RAYS Quality of
Life Scale for MS, Hamburg Quality of Life Questionnaire in MS,
and MS Symptom Impact Diary).
Three candidate instruments remained after stage one: the
MSIS-29 [23], the MS International Quality of Life question-
naire (MusiQoL) [39], and the Functional Assessment of MS
(FAMS) [40]. On the basis of practical considerations, we
decided not to progress further with the MusiQoL: its limiteduse in clinical trials to date restricted the availability of
evidence to support its responsiveness and acceptability [10].
Although we decided not to progress further with the
MusiQoL, consideration of this instrument could be a produc-
tive area for future research.
At stage two, the MSIS-29 and the FAMS were considered in
terms of the remaining criteria. Validation studies have con-
ﬁrmed the acceptability, reliability, validity, and responsiveness
of the MSIS-29 [41–46] and the FAMS [40,47–53] for a range of MS
types and clinical settings. Both instruments are well accepted by
clinicians and researchers and have frequently been used in
research and clinical trials [54]. Overall, there was more published
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 1 6 – 1 0 2 41018evidence describing the psychometric properties of the MSIS-29,
while validation studies that directly compared the MSIS-29 with
corresponding subscales of the FAMS suggest that the former
may be superior in terms of acceptability, internal consistency,
and responsiveness [54–56]. Exploratory analyses, assessing both
instruments by applying the techniques required to derive a
classiﬁcation system, identiﬁed a range of problems with the
FAMS (outlined in Supplemental Material 1 found at http://dx.doi.
org/10.1016/j.jval.2015.07.002). Therefore, we selected the MSIS-29
to form the basis of the classiﬁcation system for an MS-
speciﬁc PBM.Methods
Typically, HRQOL measures include a large number of items and
levels. This would result in unreasonable cognitive demands on
respondents to the valuation exercise required to estimate
quality weights. Therefore, the ﬁrst stage of deriving a CSPBM
involves reducing the size of the existing measure to produce a
health state classiﬁcation system that is amenable to valuation,
while minimizing the loss of descriptive information [22]. This
study adopted a ﬁve-stage process [5]:1.T
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MEstablish dimensions
2. Eliminate poorly performing items
3. Select one item to represent each dimension
4. Explore item-level reduction
5. Validate the analysisData Set for Analysis
The South West Impact of Multiple Sclerosis (SWIMS) project is a
longitudinal cohort study of adults with a clinical diagnosis of MS
or clinically isolated syndrome living in Devon and Cornwall.
Participants complete questionnaire packs, which include vari-
ous generic and condition-speciﬁc measures, and provide other
clinical and demographic data. The demographic make-up of
respondents is consistent with other published UK data and
clinical experience [57]. We randomly split an extract of SWIMS
baseline data from people with a diagnosis of MS into a develop-
ment data set (N ¼ 529) and a validation data set (N ¼ 528),able 2 – Descriptive statistics (%) for development
nd validation data sets.
haracteristic Development
(N ¼ 529)
Validation
(N ¼ 528)
emale 73 74
ale 27 26
ge o50 y 47 48.5
ge Z50 y 53 51.5
isease duration o2 y 35 33
isease duration 2–10 y 29 30
isease duration 410 y 34 31
iagnosis date not
recorded
2 6
rogressive MS 20 24
elapsing-remitting MS 27 23
enign or mild MS 2 3
S type not recorded 51 50
ote. All values are %.
S, multiple sclerosis.providing suitable sample sizes for Rasch analysis. Table 2
reports the descriptive statistics for each data set.
Analysis
The objective of the analysis was to derive a multidimensional,
patient-reported health state classiﬁcation system amenable to
valuation. The aim was to reduce the number of items in the
MSIS-29 by selecting one item to represent each of the dimen-
sions of HRQOL that were covered by the MSIS-29. Rasch analysis
was undertaken using RUMM2030 software, and psychometric
analysis was undertaken using SPSS.
Step 1: Establish Dimensions
Exploratory factor analysis was used to investigate the factor
structure of the MSIS-29. Each factor included items that repre-
sented more than one conceptually distinct dimension of HRQOL.
For example, the physical subscale included items that described
effects on social activities, as well as on physical functioning. To
address this, a conceptual framework was constructed, on the basis
of the reviewed literature, to reﬂect the main dimensions of HRQOL
in MS. Particular attention was paid to studies that directly involved
people with MS. The items of the MSIS-29 were ﬁtted to this
conceptual framework, enabling items to be selected to represent
the dimensions of HRQOL that are important to people with MS.
Step 2: Item Elimination
Rasch analysis provides a technique by which ordinal data can be
converted to continuous data. One-dimensional measures capture
an underlying trait (in this case, HRQOL or a particular dimension of
HRQOL), which is represented by a latent scale. Individual respond-
ents are located along this scale according to their levels of HRQOL.
Similarly, item response levels are located along the same scale
according to the level of HRQOL that they represent [58]. Rasch
methods can be used to assess how well individual items represent
the underlying construct [59], hence providing a means of assessing
the suitability of items for a classiﬁcation system.
For each subscale of the MSIS-29, a partial credit polytomous
Rasch model was ﬁtted and used to assess items in terms of
item-level ordering, differential item functioning (DIF), and good-
ness of ﬁt to the Rasch model.
Item-Level Ordering: Disordered Thresholds
The item-threshold map for each Rasch model was examined to
identify items with disordered thresholds. The threshold
between adjacent item responses is deﬁned as the point on the
latent scale at which either response is equally probable. Ordered
thresholds imply that more severe responses have a higher
probability of endorsement at lower levels of HRQOL. Disordered
thresholds indicate that respondents are unable to distinguish
between item response levels [59]. In this case, adjacent response
levels are collapsed and although the item should be retained in
the Rasch model, it is not suitable for inclusion in the health state
classiﬁcation [19].
Differential Item Functioning
When responses to an item differ between groups of respondents,
this is known as DIF [58]. We examined item characteristic curves
and DIF summary tables to identify items that exhibited DIF by sex,
age group, duration of disease, or type of MS. Items exhibiting
uniform DIF, where the difference in responses between groups is
consistent across the latent scale, should be adjusted by splitting
the item by the relevant person factor, creating two separate items
[59] that are retained in the Rasch models but not considered for
inclusion in the classiﬁcation system [60].
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Inclusion of respondents who do not ﬁt the expectations of the
Rasch model can cause apparent item misﬁt; therefore, all
individuals with a ﬁt residual of more than |2.5| were removed
from the analysis. The clinical and demographic characteristics
of these respondents were examined to determine whether they
constitute a speciﬁc group for whom the scale lacked general-
izability [58,59].
We applied three tests to examine how well the observed data
ﬁt the expectations of the Rasch model:1. Item-trait interaction: nonsigniﬁcant model chi-square statis-
tic (P 4 0.01) [58].2. Overall item and person ﬁt: mean item and person ﬁt
residuals will be close to zero with SDs close to one [59].3. Internal consistency: Person Separation Index greater than
0.70 [45].
Overall, goodness of ﬁt may be improved by removing indi-
vidual items that do not ﬁt the model, that is, items with ﬁt
residuals of more than |2.5| and signiﬁcant chi-square values (Po
0.05, adjusted using Bonferroni corrections for multiple tests) [59].
Items were adjusted or removed one at a time, and the
analysis was rerun after each change. Items exhibiting disordered
thresholds, DIF, or misﬁt to the Rasch model were eliminated
from consideration [5].
Step 3: Item Selection
The next step was to select the most appropriate item to represent
each conceptual dimension of HRQOL. An important feature of a
classiﬁcation system is its ability to span the full range of
condition severity. In Rasch analysis, this is represented by a wide
spread across the latent space. We judged this using item maps
and the spread of response levels at logit zero on each item’s
threshold probability curves. Individual item goodness-of-ﬁt sta-
tistics (ﬁt residuals close to zero and nonsigniﬁcant χ2) were also
taken into account, as were four psychometric criteria: feasibility
(item missing data); internal consistency (corrected item–total
correlation); distribution of responses (ﬂoor and ceiling effects);
and discriminant validity as a proxy measure of representative-
ness, using an independent samples t test to assess the item’s
ability to distinguish between two sets of respondents, grouped onFig. 1 – Conceptuthe basis of their scores on the Expanded Disease Status Scale, a
clinical measure of disease progression in MS. Preference was
given to items that spanned the full range of severity [17].
Step 4: Item-Level Reduction
Rasch analysis can identify response levels that may be
merged without losing descriptive information, offering a further
means of simplifying the classiﬁcation system [19]. Threshold
probability curves that cross or that come close to crossing
represent levels that could be merged [22].
Step 5: Validation
To validate the results of the analysis, steps 1 to 4 of the process
were repeated using the validation data set [5]. Two additional tests
were undertaken using Rasch analysis. The ﬁrst used paired t tests
to conﬁrm the unidimensionality of the ﬁnal models. The percent-
age of tests signiﬁcant at the P o 0.05 level should not exceed 5%
[16]. The second used residual correlation matrices to identify any
local dependency between items. Correlations higher than the
average correlation plus 0.2 indicate possible redundancy [61].Results
Step 1: Establish Dimensions
In the exploratory principal-components factor analysis of the
development data set, a Varimax rotation produced four factors
with Eigenvalues of more than 1, which explained 66% of the
total variance. None of the items loaded most strongly on the
fourth component, and there was no conceptual basis for group-
ing the four items that loaded on the third factor (IS07 Stiffness;
IS09 Tremor of arms/legs; IS10 Spasms in limbs; IS22 Problems
sleeping) into a separate domain. Allocating these four items to
the factor on which they had the second highest loading resulted
in a structure that mirrored the original structure of the MSIS-29,
with items 1 to 20 forming one factor (the physical subscale) and
items 21 to 29 forming the other (the psychological subscale).
This two-factor solution, which explained 50% of the total
variance, was supported by the scree plot (presented in Supple-
mental Material found at http://dx.doi.org/10.1016/j.jval.2015.07.
002).al framework.
Table 3 – Item elimination results (development data set)
Subscale Conceptual dimension Code Item description Results
Physical General/other physical
functioning
IS01 Do physically demanding tasks ✓
IS02 Grip things tightly (e.g., turning on taps) ✗ DIF (sex)
IS03 Carry things ✗ DIF (age)
IS04 Problems with your balance ✗ DIF (MS type)
IS06 Being clumsy ✗ Misﬁt
IS07 Stiffness ✗ Misﬁt
IS08 Heavy arms and/or legs ✗ Misﬁt
IS09 Tremor of your arms or legs ✗ Misﬁt
IS10 Spasms in your limbs ✗ Misﬁt
IS11 Your body not doing what you want it to do ✓
IS15 Difﬁculties using your hands in everyday tasks ✗ Misﬁt
Mobility IS05 Difﬁculties moving about indoors ✗ DIF (age)
IS14 Being stuck at home more than you would like to be ✓
IS17 Problems using transport (e.g., car, bus, train, and taxi) ✓
Bladder/bowel IS20 Needing to go to the toilet urgently? ✗ Misﬁt
General/other social and
role functioning
IS13 Limitations in your social and leisure activities at home ✓
Independence IS12 Having to depend on others to do things for you ✗ DIF (duration)
Employment IS16 Having to cut down the amount of time you spent on
work or other daily activities
✓
Unallocated items IS18 Taking longer to do things ✗ Misﬁt
IS19 Difﬁculty doing things spontaneously (e.g., going
out on the spur of the moment)
✗ Unallocated
Psychological General/other mental and
emotional well-being
IS24 Worries related to your MS ✓
IS25 Feeling anxious or tense ✗ Misﬁt
IS26 Feeling irritable, impatient, or short tempered ✓
IS28 Lack of conﬁdence ✗ DIF (MS type)
Depression IS29 Feeling depressed ✓
Fatigue IS23 Feeling mentally fatigued ✓
Cognition IS27 Problems concentrating ✓
Sleep quality IS22 Problems sleeping ✗ Misﬁt
Unallocated items IS21 Feeling unwell ✗ Unallocated
Overall goodness of ﬁt to Rasch models
following item elimination
Mean  SD P value PSI
Item ﬁt residual Person ﬁt residual
Physical subscale 0.159  1.274 0.265  0.963 0.438 0.892
Psychological subscale 0.044  0.916 0.259  0.989 0.069 0.794
✓, item retained; ✗, item eliminated; DIF, differential item functioning; PSI, Person Separation Index.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 1 6 – 1 0 2 41020Figure 1 shows the conceptual framework developed for this
analysis, which includes physical, psychological, and social
effects of MS on people’s HRQOL.
The allocation of MSIS-29 items to these conceptual dimen-
sions is presented in Table 3. The statistically conﬁrmed factors
of the MSIS-29 ﬁtted well with the conceptual dimensions: the
physical subscale included all items relating to physical and
social aspects of HRQOL, and the psychological subscale included
all items relating to the impact of nonphysical symptoms. Not all
domains of the conceptual framework were covered; no measure
can realistically include all possible dimensions [22]. Three items
(IS18, IS19, and IS21) did not ﬁt the conceptual framework,
indicating that these items do not represent a predeﬁned aspect
of HRQOL in MS and should be excluded from selection.
Step 2: Item Elimination
Table 3 summarizes the results of the item elimination analysis
(more detail is provided in Supplemental Material 2 found at
http://dx.doi.org/10.1016/j.jval.2015.07.002). No items exhibiteddisordered thresholds. Five items from the physical subscale
and one from the psychological subscale exhibited uniform DIF.
Thirty-ﬁve and 22 respondents were removed from the physical
and psychological subscale models, respectively, because of
misﬁt to the Rasch model. No commonalities were found in the
clinical or demographic characteristics of these respondents;
hence, there was no indication that the scale was unsuitable
for any particular subgroup of people with MS.
Initial overall ﬁt statistics for both subscales indicated poor ﬁt
to the Rasch model. Eight items misﬁtted the model for the
physical subscale, and two misﬁtted the model for the psycho-
logical subscale. Removing these items produced good overall ﬁt
to both models.
At the end of the item elimination phase, ﬁve conceptual
dimensions were represented by one item each: General/other
social/role functioning (IS13), Employment (IS16), Fatigue (IS23),
Cognition (IS27), and Depression (IS29). A further three dimen-
sions each had two remaining items: General/other physical
functioning (IS01 and IS11), Mobility (IS14 and IS17), and Gen-
eral/other mental/emotional well-being (IS24 and IS26). Three
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 1 6 – 1 0 2 4 1021dimensions were no longer represented because their constituent
items had been eliminated: Independence (IS12), Bladder/bowel
function (IS20), and Sleep quality (IS22).
Step 3: Item Selection
The aims of the item selection phase were to conﬁrm the
suitability of the items remaining as the sole representative of
a dimension and to decide which items should be selected to
represent the General/other physical functioning, Mobility, and
General/other mental well-being dimensions. The results are
summarized in Table 4.
All items that remained as the sole representative of a
dimension had adequate spread across the latent space and
well-spaced threshold probability curves at logit zero. Items
IS13 and IS16 performed well across all criteria; IS23 and IS27
failed to meet the threshold for internal consistency but per-
formed well against the other criteria; IS29 struggled against
some criteria but exhibited the strongest internal consistency of
any item from the psychological subscale.
General/Other Physical Functioning
IS01 showed a wider spread across the latent space than did IS11
and performed well on all criteria. IS11 had better spaced thresh-
old probability curves but had a high ﬁt residual and a relatively
high proportion of missing data.
Mobility
Although IS14 and IS17 had equivalent spread across the latent
space, the thresholds of item IS14 spanned logit zero whereas all
thresholds for item IS17 were above logit zero, and the threshold
probability curves for item IS14 were more widely spaced. IS14
had a high ﬁt residual, whereas IS17 had a large ceiling effect.
General/Other Mental Well-Being
Item IS26 showed a wider spread of levels across the latent space,
better spaced threshold probability curves, and good performance
across all criteria. Item IS24 had a high ﬁt residual, signiﬁcant P
value, and poor internal consistency.
These results supported the selection of items IS01, IS13, IS14,
IS16, IS23, IS26, IS27, and IS29 for the classiﬁcation system.
Step 4: Item-Level Reduction
Threshold probability curves provided no evidence to suggest
that the number of item levels could be reduced.
Step 5: Validation
The analysis was repeated using the validation data set (detailed
results are presented in Supplemental Material 3 found at http://
dx.doi.org/10.1016/j.jval.2015.07.002). The only difference was
that item IS12, representing the Independence dimension, passed
all item elimination tests during analysis of the validation data
set but was eliminated during analysis of the development data
set because of DIF: people who had MS for 10 or more years
reported that they were less bothered by “having to depend on
others” than would be expected compared with those in the
lower duration groups. For people with severe MS, research
suggests that support from others can either increase or decrease
their sense of independence [12], providing a possible explan-
ation for the DIF observed in the development data set. There-
fore, this item was excluded from the classiﬁcation system.
To test the impact of the unallocated items (IS18, IS19, and
IS21), we repeated the analysis with these items excluded. This
made no difference to the results. On using the Rasch test of
unidimensionality in the development data set, we found that
In the past two weeks, how much has your 
MS limited your ability to … Not at all A little Moderately Extremely 
Do physically demanding tasks? 1 2 3 4 
In the past two weeks, how much have you 
been bothered by … Not at all A little Moderately Extremely 
Limitations in your social and leisure 
activities at home? 1 2 3 4 
Being stuck at home more than you would 
like to be? 1 2 3 4 
Having to cut down the amount of time you 
spent on work or other daily activities? 1 2 3 4 
4321?deugitafyllatnemgnileeF
Feeling irritable, impatient or short-
tempered? 1 2 3 4 
4321?gnitartnecnocsmelborP
Feeling depressed? 1 2 3 4 
Fig. 2 – MSIS-8D classiﬁcation system. MS, multiple sclerosis; MSIS-8D, eight-dimensional Multiple Sclerosis Impact Scale.
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and 2.51% were signiﬁcant for the psychological subscale. In the
validation data set, 3.08% were signiﬁcant for the physical
subscale and 2.68% were signiﬁcant for the psychological sub-
scale. This supported the unidimensionality of all four models.
Residual correlations were examined between the items selected
for the classiﬁcation system. In the development data set, no
local dependency was apparent. In the validation data set, we
found a correlation between items IS13 and IS14. These items
represent different dimensions of HRQOL in MS and were not
correlated in the development data set; therefore, both were
included in the classiﬁcation system.
The MSIS-8D Classiﬁcation System
Analysis of both data sets produced a classiﬁcation system
comprising eight items, each of which represents one of the
following conceptual dimensions of HRQOL in MS: general phys-
ical function, mobility, employment, social function, fatigue,
cognition, depression, and general emotional well-being. Each
item has four levels. In total, the MSIS-8D classiﬁcation system
(Fig. 2) describes 65,536 health states.Discussion
We describe the ﬁrst stage in developing a CSPBM for MS,
presenting the MSIS-8D. Building on strong research method-
ology [5], we have derived the MSIS-8D classiﬁcation system from
an existing HRQOL measure, the MSIS-29. The MSIS-8D covers
important dimensions of HRQOL in MS and is suitable for use in a
valuation survey. The next stage of the research will involve
preference elicitation and related regression-based statistical
modeling to derive quality weights for all health states described
by the MSIS-8D. This will result in a CSPBM that is capable of
generating health state values for the estimation of QALYs, for
use in health policy settings including the economic evaluation of
treatments for MS.
We present a strong rationale for the selection of the MSIS-29
as the basis for this MS-speciﬁc PBM. All available measures of
HRQOL in MS have some limitations, but the MSIS-29 emerged as
one of the strongest candidates. Developing a CSPBM from an
existing measure of HRQOL offers a number of advantages.
Adapting a well-accepted and frequently used measure, such as
the MSIS-29, enables retrospective analyses to be undertakenusing existing data and increases the likelihood that the measure
will be used in future studies [22].
Both subscales of the MSIS-29 contained items that repre-
sented different dimensions of HRQOL. We developed a novel
approach to deal with this: analyzing the relevant literature to
build a conceptual framework of HRQOL in MS, to which the
items of the instrument were mapped, ensuring that the main
conceptually independent dimensions of HRQOL were repre-
sented in the classiﬁcation system. This builds on previous
research, in which the original dimensional structure of an
instrument has been used to guide the selection of items, despite
a lack of statistical independence between dimensions [16].
The use of condition-speciﬁc measures to inform economic
evaluation has generated some debate [1,5,22,62–64]. Some com-
mentators argue that to compare the results of different eco-
nomic evaluations, health outcomes must be assessed using the
same classiﬁcation system. This requirement, however, is not
found in other areas of economics or in the earlier QALY
literature. Brazier et al. [5] suggest that provided the same
preference elicitation methods are used to obtain quality weights,
comparability can be achieved between different classiﬁcation
systems. This view has informed the methods used to develop
the MSIS-8D. Notwithstanding this, some problems with compa-
rability remain, and these arise largely because of the limited
coverage of CSPBMs relative to generic measures. CSPBMs may be
incapable of capturing adverse effects of interventions that fall
outside the dimensions covered by the classiﬁcation system, or of
picking up effects on comorbidities. They may be prone to
focusing effects, where the impact of the condition is overesti-
mated because respondents to the valuation survey concentrate
solely on the dimensions included in the classiﬁcation system
rather than viewing them in a wider context. Respondents may
take into account aspects of health that are excluded from the
classiﬁcation system, potentially inﬂuencing their preferences
between health states and affecting the survey results. Another
concern is the relationship between perfect health and the best
possible state described by the classiﬁcation system. It is feasible
for a person to attain the best possible health state according to a
speciﬁc instrument, but to have other health problems not
covered by its classiﬁcation system. The instrument-speciﬁc
nature of “best possible” health states makes it difﬁcult to
compare results between different PBMs [5].
These disadvantages are arguably less important when the
condition of interest is the dominant factor in determining
HRQOL [22], as is likely to be the case for people with MS. In
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 1 6 – 1 0 2 4 1023addition, because of the wide variety of ways in which MS affects
people’s HRQOL, the classiﬁcation system of the MSIS-8D encom-
passes a broader range of dimensions than do many other
CSPBMs. Deciding whether to use a CSPBM rather than a generic
PBM invariably involves a trade-off between the advantages and
disadvantages of CSPBMs in relation to the condition of interest
[5]. In the case of MS, the potential limitations of existing generic
measures [14], the broad scope of the MSIS-8D classiﬁcation
system, and the likely dominant nature of MS in determining
HRQOL all support the development and use of a CSPBM.
Deriving a classiﬁcation system from an existing measure
restricts its coverage to the HRQOL dimensions covered by the
original instrument and provides limited ﬂexibility in terms of the
items available to represent each dimension. Another limitation of
this study is that the classiﬁcation system has been both developed
and validated using the same data set. Although the SWIMS cohort
has been shown to be representative of the MS population in terms
of various demographic and clinical criteria [57], data on MS type
were missing for nearly half of the cases and the cohort is
geographically limited to the South West of England. Further
validation of the MSIS-8D, using other data sets, would be beneﬁ-
cial. This study has aimed to produce a classiﬁcation system that is
suitable for all people with MS. Further research could involve
repeating the analysis for subgroups of people with MS to inves-
tigate whether selected MSIS-29 items may differ between sub-
groups, for example, between people with different types of MS.Conclusions
Best practice methods for converting an HRQOL measure into a
classiﬁcation system for a CSPBM, which combine traditional
psychometric methods with Rasch analysis, have been used
successfully to develop an MS-speciﬁc classiﬁcation system. We
further developed these methods by designing a standardized
process for selecting an appropriate baseline measure and by
using a conceptual framework to guide item selection, both of
which proved to be useful additions to the existing methodology.
Research is underway to estimate a tariff of quality weights for all
MSIS-8D health states. A reliable and valid CSPBM for MS will be a
valuable addition to the methods available for the estimation of
QALYs for MS health states to support the assessment of HRQOL
and the economic evaluation of treatments for people with MS.
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